D.E. Shaw & Co
CTMX icon

D.E. Shaw & Co’s CytomX Therapeutics CTMX Stock Holding History

D.E. Shaw & Co’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,811
Closed -$23.6K – 4537
2024
Q1 		$23.6K Sell
10,811
-766
-7% -$1.41K ﹤0.01% 4112
2023
Q4 		$17.9K Sell
11,577
-61,917
-84% -$81.4K ﹤0.01% 4076
2023
Q3 		$94.8K Sell
73,494
-56,966
-44% -$89.7K ﹤0.01% 3855
2023
Q2 		$224K Sell
130,460
-170,381
-57% -$283K ﹤0.01% 3708
2023
Q1 		$454K Sell
300,841
-317,533
-51% -$718K ﹤0.01% 3597
2022
Q4 		$989K Buy
618,374
+128,744
+26% +$190K ﹤0.01% 3460
2022
Q3 		$710K Buy
489,630
+242,153
+98% +$373K ﹤0.01% 3827
2022
Q2 		$453K Buy
247,477
+77,526
+46% +$148K ﹤0.01% 4146
2022
Q1 		$454K Buy
+169,951
New +$653K ﹤0.01% 4427
2021
Q4 		– Sell
-26,297
Closed -$134K – 5459
2021
Q3 		$134K Sell
26,297
-163,147
-86% -$873K ﹤0.01% 4663
2021
Q2 		$1.2M Sell
189,444
-129,037
-41% -$1M ﹤0.01% 3392
2021
Q1 		$2.46M Sell
318,481
-297,518
-48% -$2.35M ﹤0.01% 2420
2020
Q4 		$4.04M Buy
615,999
+103,511
+20% +$739K ﹤0.01% 2042
2020
Q3 		$3.41M Buy
512,488
+147,391
+40% +$1.09M ﹤0.01% 1975
2020
Q2 		$3.04M Sell
365,097
-157,555
-30% -$1.46M ﹤0.01% 2073
2020
Q1 		$4.01M Sell
522,652
-177,449
-25% -$1.24M 0.01% 1629
2019
Q4 		$5.82M Buy
700,101
+363,097
+108% +$2.45M 0.01% 1608
2019
Q3 		$2.49M Buy
337,004
+4,810
+1% +$47.4K ﹤0.01% 2200
2019
Q2 		$3.73M Sell
332,194
-47,560
-13% -$499K ﹤0.01% 1805
2019
Q1 		$4.08M Buy
379,754
+246,072
+184% +$3.64M 0.01% 1673
2018
Q4 		$2.02M Buy
133,682
+11,365
+9% +$169K ﹤0.01% 2139
2018
Q3 		$2.26M Buy
122,317
+14,264
+13% +$325K ﹤0.01% 2109
2018
Q2 		$2.47M Buy
108,053
+30,538
+39% +$780K ﹤0.01% 2067
2018
Q1 		$2.21M Buy
77,515
+47,034
+154% +$1.34M ﹤0.01% 1981
2017
Q4 		$643K Buy
30,481
+17,998
+144% +$373K ﹤0.01% 2833
2017
Q3 		$227K Buy
+12,483
New +$195K ﹤0.01% 3255
2016
Q1 		– Sell
-21,257
Closed -$444K – 3473
2015
Q4 		$444K Buy
+21,257
New +$336K ﹤0.01% 3149

Other funds holding CTMX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

D.E. Shaw & Co's CTMX Position: Q2 2024 in Review

D.E. Shaw & Co sold out of CytomX Therapeutics (CTMX) in Q2 2024, closing a stake of 10,811 shares — an estimated $23.6K sold.

D.E. Shaw & Co first reported a position in CTMX in Q4 2015 and held it in 27 quarters. The position peaked at $5.82M in Q4 2019. 74 funds tracked by Wall St. Rank hold CTMX as of Q2 2024.

  • D.E. Shaw & Co reported no remaining CytomX Therapeutics position as of Q2 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 10,811 CytomX Therapeutics shares in Q2 2024, an estimated $23.6K.
  • D.E. Shaw & Co first reported a position in CytomX Therapeutics in Q4 2015 and held it in 27 quarters.
  • D.E. Shaw & Co's CytomX Therapeutics position peaked at $5.82M in Q4 2019.
  • 74 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2024.

Based on D.E. Shaw & Co's 13F filing for Q2 2024, filed 14 Aug 2024.